Mouse brain plasmalogens are targets for hypochlorous acid-mediated modification in vitro and in vivo

Free Radical Biology and Medicine

Volumn 49, Issue 11, 2010, Pages 1655-1665

  Üllen, Andreas ^a   Fauler, Günter ^a   Köfeler, Harald ^a   Waltl, Sabine ^a   Nusshold, Christoph ^a   Bernhart, Eva ^a   Reicher, Helga ^a   Leis, Hans Jörg ^b   Wintersperger, Andrea ^a   Malle, Ernst ^a   Sattler, Wolfgang ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

Chlorinative stress; Endotoxin; Free radicals; Hypochlorite; Lipotoxicity; Myeloperoxidase; Neuroinflammation

Indexed keywords

ALDEHYDE DERIVATIVE; CHLORIDE ION; CYCLOOXYGENASE 2; ETHER DERIVATIVE; GLYCEROPHOSPHOLIPID; HYDROGEN PEROXIDE; HYPOCHLOROUS ACID; LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHOLIPID; MESSENGER RNA; MYELOPEROXIDASE; PHOSPHATIDYLETHANOLAMINE; TUMOR NECROSIS FACTOR ALPHA; VINYL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEVELOPMENT; CONTROLLED STUDY; IN VITRO SELECTION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIQUID CHROMATOGRAPHY; MALE; MOUSE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; SYNAPTIC TRANSMISSION; UPREGULATION;

ANIMALS; BRAIN; BRAIN CHEMISTRY; CELLS, CULTURED; ETHANOLAMINES; HYPOCHLOROUS ACID; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; OXIDATION-REDUCTION; PHOSPHOLIPIDS; PHOSPHORYLCHOLINE; PLASMALOGENS; TRANSCRIPTION, GENETIC;

EID: 78049367417     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2010.08.025     Document Type: Article

References (68)

1. Halliwell B. Oxidative stress and neurodegeneration: where are we now?. J. Neurochem. 2006, 97:1634-1658.
2. Yap Y.W., Whiteman M., Cheung N.S. Chlorinative stress: an under appreciated mediator of neurodegeneration?. Cell. Signal. 2007, 19:219-228.
3. Klebanoff S.J. Myeloperoxidase: friend and foe. J. Leukoc. Biol. 2005, 77:598-625.
4. Hazell L.J., Arnold L., Flowers D., Waeg G., Malle E., Stocker R. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J. Clin. Invest. 1996, 97:1535-1544.
5. 2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins. Eur. J. Biochem. 2000, 267:4495-4503.
6. Grone H.J., Grone E.F., Malle E. Immunohistochemical detection of hypochlorite-modified proteins in glomeruli of human membranous glomerulonephritis. Lab. Invest. 2002, 82:5-14.
7. Thukkani A.K., McHowat J., Hsu F.F., Brennan M.L., Hazen S.L., Ford D.A. Identification of alpha-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions. Circulation 2003, 108:3128-3133.
8. Rudolph V., Andrie R.P., Rudolph T.K., Friedrichs K., Klinke A., Hirsch-Hoffmann B., Schwoerer A.P., Lau D., Fu X., Klingel K., Sydow K., Didie M., Seniuk A., von Leitner E.C., Szoecs K., Schrickel J.W., Treede H., Wenzel U., Lewalter T., Nickenig G., Zimmermann W.H., Meinertz T., Boger R.H., Reichenspurner H., Freeman B.A., Eschenhagen T., Ehmke H., Hazen S.L., Willems S., Baldus S. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat. Med. 2010, 16:470-474.
9. Nagra R.M., Becher B., Tourtellotte W.W., Antel J.P., Gold D., Paladino T., Smith R.A., Nelson J.R., Reynolds W.F. Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J. Neuroimmunol. 1997, 78:97-107.
10. Chen J.W., Breckwoldt M.O., Aikawa E., Chiang G., Weissleder R. Myeloperoxidase-targeted imaging of active inflammatory lesions in murine experimental autoimmune encephalomyelitis. Brain 2008, 131:1123-1133.
11. Gray E., Thomas T.L., Betmouni S., Scolding N., Love S. Elevated activity and microglial expression of myeloperoxidase in demyelinated cerebral cortex in multiple sclerosis. Brain Pathol. 2008, 18:86-95.
12. Marik C., Felts P.A., Bauer J., Lassmann H., Smith K.J. Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity?. Brain 2007, 130:2800-2815.
13. Spickett C.M. Chlorinated lipids and fatty acids: an emerging role in pathology. Pharmacol. Ther. 2007, 115:400-409.
14. Kawai Y., Kiyokawa H., Kimura Y., Kato Y., Tsuchiya K., Terao J. Hypochlorous acid-derived modification of phospholipids: characterization of aminophospholipids as regulatory molecules for lipid peroxidation. Biochemistry 2006, 45:14201-14211.
15. Flemmig J., Spalteholz H., Schubert K., Meier S., Arnhold J. Modification of phosphatidylserine by hypochlorous acid. Chem. Phys. Lipids 2009, 161:44-50.
16. Nusshold C., Kollroser M., Kofeler H., Rechberger G., Reicher H., Ullen A., Bernhart E., Waltl S., Kratzer I., Hermetter A., Hackl H., Trajanoski Z., Hrzenjak A., Malle E., Sattler W. Hypochlorite modification of sphingomyelin generates chlorinated lipid species that induce apoptosis and proteome alterations in dopaminergic PC12 neurons in vitro. Free Radic. Biol. Med. 2010, 48:1588-1600.
17. Gorgas K., Teigler A., Komljenovic D., Just W.W. The ether lipid-deficient mouse: tracking down plasmalogen functions. Biochim. Biophys. Acta 2006, 1763:1511-1526.
18. Marsche G., Heller R., Fauler G., Kovacevic A., Nuszkowski A., Graier W., Sattler W., Malle E. 2-Chlorohexadecanal derived from hypochlorite-modified high-density lipoprotein-associated plasmalogen is a natural inhibitor of endothelial nitric oxide biosynthesis. Arterioscler. Thromb. Vasc. Biol. 2004, 24:2302-2306.
19. Thukkani A.K., Hsu F.F., Crowley J.R., Wysolmerski R.B., Albert C.J., Ford D.A. Reactive chlorinating species produced during neutrophil activation target tissue plasmalogens: production of the chemoattractant, 2-chlorohexadecanal. J. Biol. Chem. 2002, 277:3842-3849.
20. Thukkani A.K., Albert C.J., Wildsmith K.R., Messner M.C., Martinson B.D., Hsu F.F., Ford D.A. Myeloperoxidase-derived reactive chlorinating species from human monocytes target plasmalogens in low density lipoprotein. J. Biol. Chem. 2003, 278:36365-36372.
21. Thukkani A.K., Martinson B.D., Albert C.J., Vogler G.A., Ford D.A. Neutrophil-mediated accumulation of 2-ClHDA during myocardial infarction: 2-ClHDA-mediated myocardial injury. Am. J. Physiol. Heart Circ. Physiol. 2005, 288:H2955-H2964.
22. Rodemer C., Thai T.P., Brugger B., Kaercher T., Werner H., Nave K.A., Wieland F., Gorgas K., Just W.W. Inactivation of ether lipid biosynthesis causes male infertility, defects in eye development and optic nerve hypoplasia in mice. Hum. Mol. Genet. 2003, 12:1881-1895.
23. Thai T.P., Rodemer C., Jauch A., Hunziker A., Moser A., Gorgas K., Just W.W. Impaired membrane traffic in defective ether lipid biosynthesis. Hum. Mol. Genet. 2001, 10:127-136.
24. Komljenovic D., Sandhoff R., Teigler A., Heid H., Just W.W., Gorgas K. Disruption of blood-testis barrier dynamics in ether-lipid-deficient mice. Cell Tissue Res. 2009, 337:281-299.
25. Teigler A., Komljenovic D., Draguhn A., Gorgas K., Just W.W. Defects in myelination, paranode organization and Purkinje cell innervation in the ether lipid-deficient mouse cerebellum. Hum. Mol. Genet. 2009, 18:1897-1908.
26. Steinberg S.J., Dodt G., Raymond G.V., Braverman N.E., Moser A.B., Moser H.W. Peroxisome biogenesis disorders. Biochim. Biophys. Acta 2006, 1763:1733-1748.
27. Brites P., Mooyer P.A., El Mrabet L., Waterham H.R., Wanders R.J. Plasmalogens participate in very-long-chain fatty acid-induced pathology. Brain 2009, 132:482-492.
28. Han X., Holtzman D.M., McKeel D.W. Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J. Neurochem. 2001, 77:1168-1180.
29. Han X. Potential mechanisms contributing to sulfatide depletion at the earliest clinically recognizable stage of Alzheimer's disease: a tale of shotgun lipidomics. J. Neurochem. 2007, 103(Suppl. 1):171-179.
30. Ginsberg L., Rafique S., Xuereb J.H., Rapoport S.I., Gershfeld N.L. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain. Brain Res. 1995, 698:223-226.
31. Han X.L., Gross R.W. Plasmenylcholine and phosphatidylcholine membrane bilayers possess distinct conformational motifs. Biochemistry 1990, 29:4992-4996.
32. Glaser P.E., Gross R.W. Plasmenylethanolamine facilitates rapid membrane fusion: a stopped-flow kinetic investigation correlating the propensity of a major plasma membrane constituent to adopt an HII phase with its ability to promote membrane fusion. Biochemistry 1994, 33:5805-5812.
33. Folch J., Lees M., Sloane Stanley G.H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 1957, 226:497-509.
34. O'Brien J.S., Sampson E.L. Lipid composition of the normal human brain: gray matter, white matter, and myelin. J. Lipid Res. 1965, 6:537-544.
35. Pfaffl M.W., Horgan G.W., Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002, 30:e36.
36. Albert C.J., Crowley J.R., Hsu F.F., Thukkani A.K., Ford D.A. Reactive chlorinating species produced by myeloperoxidase target the vinyl ether bond of plasmalogens: identification of 2-chlorohexadecanal. J. Biol. Chem. 2001, 276:23733-23741.
37. Messner M.C., Albert C.J., Hsu F.F., Ford D.A. Selective plasmenylcholine oxidation by hypochlorous acid: formation of lysophosphatidylcholine chlorohydrins. Chem. Phys. Lipids 2006, 144:34-44.
38. Yang K., Zhao Z., Gross R.W., Han X. Shotgun lipidomics identifies a paired rule for the presence of isomeric ether phospholipid molecular species. PLoS ONE 2007, 2:e1368.
39. Taguchi R., Ishikawa M. Precise and global identification of phospholipid molecular species by an Orbitrap mass spectrometer and automated search engine Lipid Search. J. Chromatogr. A 2010, 1217:4229-4239.
40. Glaser P.E., Gross R.W. Rapid plasmenylethanolamine-selective fusion of membrane bilayers catalyzed by an isoform of glyceraldehyde-3-phosphate dehydrogenase: discrimination between glycolytic and fusogenic roles of individual isoforms. Biochemistry 1995, 34:12193-12203.
41. Farooqui A.A. Studies on plasmalogen-selective phospholipase A(2) in brain. Mol. Neurobiol. 2010, 41:267-273.
42. Skaff O., Pattison D.I., Davies M.J. The vinyl ether linkages of plasmalogens are favored targets for myeloperoxidase-derived oxidants: a kinetic study. Biochemistry 2008, 47:8237-8245.
43. Pattison D.I., Davies M.J. Kinetic analysis of the role of histidine chloramines in hypochlorous acid mediated protein oxidation. Biochemistry 2005, 44:7378-7387.
44. Richter G., Schober C., Suss R., Fuchs B., Birkemeyer C., Schiller J. Comparison of the positive and negative ion electrospray ionization and matrix-assisted laser desorption ionization-time-of-flight mass spectra of the reaction products of phosphatidylethanolamines and hypochlorous acid. Anal. Biochem. 2008, 376:157-159.
45. Lessig J., Schiller J., Arnhold J., Fuchs B. Hypochlorous acid-mediated generation of glycerophosphocholine from unsaturated plasmalogen glycerophosphocholine lipids. J. Lipid Res. 2007, 48:1316-1324.
46. Panasenko O.M., Spalteholz H., Schiller J., Arnhold J. Myeloperoxidase-induced formation of chlorohydrins and lysophospholipids from unsaturated phosphatidylcholines. Free Radic. Biol. Med. 2003, 34:553-562.
47. Liu Y., Qin L., Wilson B., Wu X., Qian L., Granholm A.C., Crews F.T., Hong J.S. Endotoxin induces a delayed loss of TH-IR neurons in substantia nigra and motor behavioral deficits. Neurotoxicology 2008, 29:864-870.
48. Banks W.A., Robinson S.M. Minimal penetration of lipopolysaccharide across the murine blood-brain barrier. Brain Behav. Immun. 2010, 24:102-109.
49. Qin L., Wu X., Block M.L., Liu Y., Breese G.R., Hong J.S., Knapp D.J., Crews F.T. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55:453-462.
50. Farooqui A.A., Horrocks L.A., Farooqui T. Modulation of inflammation in brain: a matter of fat. J. Neurochem. 2007, 101:577-599.
51. Breckwoldt M.O., Chen J.W., Stangenberg L., Aikawa E., Rodriguez E., Qiu S., Moskowitz M.A., Weissleder R. Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase. Proc. Natl Acad. Sci. USA 2008, 105:18584-18589.
52. Choi D.K., Pennathur S., Perier C., Tieu K., Teismann P., Wu D.C., Jackson-Lewis V., Vila M., Vonsattel J.P., Heinecke J.W., Przedborski S. Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J. Neurosci. 2005, 25:6594-6600.
53. Reynolds W.F., Rhees J., Maciejewski D., Paladino T., Sieburg H., Maki R.A., Masliah E. Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp. Neurol. 1999, 155:31-41.
54. Green P.S., Mendez A.J., Jacob J.S., Crowley J.R., Growdon W., Hyman B.T., Heinecke J.W. Neuronal expression of myeloperoxidase is increased in Alzheimer's disease. J. Neurochem. 2004, 90:724-733.
55. Ji K.A., Yang M.S., Jeong H.K., Min K.J., Kang S.H., Jou I., Joe E.H. Resident microglia die and infiltrated neutrophils and monocytes become major inflammatory cells in lipopolysaccharide-injected brain. Glia 2007, 55:1577-1588.
56. Maki R.A., Tyurin V.A., Lyon R.C., Hamilton R.L., DeKosky S.T., Kagan V.E., Reynolds W.F. Aberrant expression of myeloperoxidase in astrocytes promotes phospholipid oxidation and memory deficits in a mouse model of Alzheimer disease. J. Biol. Chem. 2009, 284:3158-3169.
57. Anbukumar D.S., Shornick L.P., Albert C.J., Steward M.M., Zoeller R.A., Neumann W.L., Ford D.A. Chlorinated lipid species in activated human neutrophils: lipid metabolites of 2-chlorohexadecanal. J. Lipid Res. 2010, 51:1085-1092.
58. Rizzo W.B., Carney G. Sjogren-Larsson syndrome: diversity of mutations and polymorphisms in the fatty aldehyde dehydrogenase gene (ALDH3A2). Hum. Mutat. 2005, 26:1-10.
59. Wildsmith K.R., Albert C.J., Anbukumar D.S., Ford D.A. Metabolism of myeloperoxidase-derived 2-chlorohexadecanal. J. Biol. Chem. 2006, 281:16849-16860.
60. Wildsmith K.R., Albert C.J., Hsu F.F., Kao J.L., Ford D.A. Myeloperoxidase-derived 2-chlorohexadecanal forms Schiff bases with primary amines of ethanolamine glycerophospholipids and lysine. Chem. Phys. Lipids 2006, 139:157-170.
61. Stadelmann-Ingrand S., Pontcharraud R., Fauconneau B. Evidence for the reactivity of fatty aldehydes released from oxidized plasmalogens with phosphatidylethanolamine to form Schiff base adducts in rat brain homogenates. Chem. Phys. Lipids 2004, 131:93-105.
62. Rausch P.G., Moore T.G. Granule enzymes of polymorphonuclear neutrophils: a phylogenetic comparison. Blood 1975, 46:913-919.
63. Noguchi N., Nakano K., Aratani Y., Koyama H., Kodama T., Niki E. Role of myeloperoxidase in the neutrophil-induced oxidation of low density lipoprotein as studied by myeloperoxidase-knockout mouse. J. Biochem. 2000, 127:971-976.
64. Cimini A., Bernardo A., Cifone M.G., Di Marzio L., Di Loreto S. TNFalpha downregulates PPARdelta expression in oligodendrocyte progenitor cells: implications for demyelinating diseases. Glia 2003, 41:3-14.
65. Singh I., Paintlia A.S., Khan M., Stanislaus R., Paintlia M.K., Haq E., Singh A.K., Contreras M.A. Impaired peroxisomal function in the central nervous system with inflammatory disease of experimental autoimmune encephalomyelitis animals and protection by lovastatin treatment. Brain Res. 2004, 1022:1-11.
66. Goodenowe D.B., Cook L.L., Liu J., Lu Y., Jayasinghe D.A., Ahiahonu P.W., Heath D., Yamazaki Y., Flax J., Krenitsky K.F., Sparks D.L., Lerner A., Friedland R.P., Kudo T., Kamino K., Morihara T., Takeda M., Wood P.L. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia. J. Lipid Res. 2007, 48:2485-2498.
67. Moraitou M., Dimitriou E., Zafeiriou D., Reppa C., Marinakis T., Sarafidou J., Michelakakis H. Plasmalogen levels in Gaucher disease. Blood Cells Mol. Dis. 2008, 41:196-199.
68. Murphy E.J., Schapiro M.B., Rapoport S.I., Shetty H.U. Phospholipid composition and levels are altered in Down syndrome brain. Brain Res. 2000, 867:9-18.